Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.49
FLDM's Cash to Debt is ranked lower than
72% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. FLDM: 0.49 )
Ranked among companies with meaningful Cash to Debt only.
FLDM' s Cash to Debt Range Over the Past 10 Years
Min: 0.32  Med: 5.18 Max: No Debt
Current: 0.49
Equity to Asset 0.31
FLDM's Equity to Asset is ranked lower than
82% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. FLDM: 0.31 )
Ranked among companies with meaningful Equity to Asset only.
FLDM' s Equity to Asset Range Over the Past 10 Years
Min: -7.63  Med: 0.39 Max: 0.89
Current: 0.31
-7.63
0.89
F-Score: 4
Z-Score: -0.64
M-Score: -2.27
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -43.72
FLDM's Operating margin (%) is ranked lower than
66% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.66 vs. FLDM: -43.72 )
Ranked among companies with meaningful Operating margin (%) only.
FLDM' s Operating margin (%) Range Over the Past 10 Years
Min: -338.59  Med: -44.51 Max: -26.2
Current: -43.72
-338.59
-26.2
Net-margin (%) -46.48
FLDM's Net-margin (%) is ranked lower than
67% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.98 vs. FLDM: -46.48 )
Ranked among companies with meaningful Net-margin (%) only.
FLDM' s Net-margin (%) Range Over the Past 10 Years
Min: -368.13  Med: -52.42 Max: -23.22
Current: -46.48
-368.13
-23.22
ROE (%) -40.08
FLDM's ROE (%) is ranked lower than
71% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. FLDM: -40.08 )
Ranked among companies with meaningful ROE (%) only.
FLDM' s ROE (%) Range Over the Past 10 Years
Min: -42.81  Med: -24.15 Max: -16.77
Current: -40.08
-42.81
-16.77
ROA (%) -13.73
FLDM's ROA (%) is ranked lower than
58% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.60 vs. FLDM: -13.73 )
Ranked among companies with meaningful ROA (%) only.
FLDM' s ROA (%) Range Over the Past 10 Years
Min: -67.71  Med: -49.47 Max: -14.33
Current: -13.73
-67.71
-14.33
ROC (Joel Greenblatt) (%) -161.91
FLDM's ROC (Joel Greenblatt) (%) is ranked lower than
64% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.03 vs. FLDM: -161.91 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
FLDM' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -805.14  Med: -231.92 Max: -138.28
Current: -161.91
-805.14
-138.28
Revenue Growth (3Y)(%) 20.40
FLDM's Revenue Growth (3Y)(%) is ranked higher than
88% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.70 vs. FLDM: 20.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
FLDM' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -45.80 Max: 20.4
Current: 20.4
0
20.4
EBITDA Growth (3Y)(%) 11.60
FLDM's EBITDA Growth (3Y)(%) is ranked higher than
69% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. FLDM: 11.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
FLDM' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -58.80 Max: 11.6
Current: 11.6
0
11.6
EPS Growth (3Y)(%) 1.60
FLDM's EPS Growth (3Y)(%) is ranked higher than
53% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. FLDM: 1.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
FLDM' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -57.80 Max: 1.6
Current: 1.6
0
1.6
» FLDM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

FLDM Guru Trades in Q1 2015

RS Investment Management 909,448 sh (+14.62%)
PRIMECAP Management 3,725,832 sh (-0.03%)
» More
Q2 2015

FLDM Guru Trades in Q2 2015

Steven Cohen 63,400 sh (New)
PRIMECAP Management 4,069,132 sh (+9.21%)
RS Investment Management Sold Out
» More
Q3 2015

FLDM Guru Trades in Q3 2015

Jim Simons 161,512 sh (New)
PRIMECAP Management 4,266,432 sh (+4.85%)
Steven Cohen Sold Out
» More
Q4 2015

FLDM Guru Trades in Q4 2015

Columbia Wanger 1,788,773 sh (New)
Jim Simons 205,000 sh (+26.93%)
» More
» Details

Insider Trades

Latest Guru Trades with FLDM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.52
FLDM's P/B is ranked higher than
74% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.67 vs. FLDM: 1.52 )
Ranked among companies with meaningful P/B only.
FLDM' s P/B Range Over the Past 10 Years
Min: 1.32  Med: 4.88 Max: 12.53
Current: 1.52
1.32
12.53
P/S 1.46
FLDM's P/S is ranked higher than
69% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. FLDM: 1.46 )
Ranked among companies with meaningful P/S only.
FLDM' s P/S Range Over the Past 10 Years
Min: 0.93  Med: 6.44 Max: 16.67
Current: 1.46
0.93
16.67
Current Ratio 5.29
FLDM's Current Ratio is ranked higher than
76% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. FLDM: 5.29 )
Ranked among companies with meaningful Current Ratio only.
FLDM' s Current Ratio Range Over the Past 10 Years
Min: 1.13  Med: 4.86 Max: 8.73
Current: 5.29
1.13
8.73
Quick Ratio 4.60
FLDM's Quick Ratio is ranked higher than
74% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. FLDM: 4.60 )
Ranked among companies with meaningful Quick Ratio only.
FLDM' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 4.29 Max: 8.11
Current: 4.6
0.86
8.11
Days Inventory 139.75
FLDM's Days Inventory is ranked lower than
71% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.26 vs. FLDM: 139.75 )
Ranked among companies with meaningful Days Inventory only.
FLDM' s Days Inventory Range Over the Past 10 Years
Min: 102.81  Med: 149.83 Max: 443.32
Current: 139.75
102.81
443.32
Days Sales Outstanding 81.00
FLDM's Days Sales Outstanding is ranked lower than
63% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.71 vs. FLDM: 81.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
FLDM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.11  Med: 89.97 Max: 124.82
Current: 81
54.11
124.82
Days Payable 47.70
FLDM's Days Payable is ranked lower than
56% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.88 vs. FLDM: 47.70 )
Ranked among companies with meaningful Days Payable only.
FLDM' s Days Payable Range Over the Past 10 Years
Min: 50.42  Med: 99.44 Max: 283.05
Current: 47.7
50.42
283.05

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.23
FLDM's Price/Median PS Value is ranked higher than
91% of the 226 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.97 vs. FLDM: 0.23 )
Ranked among companies with meaningful Price/Median PS Value only.
FLDM' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.15  Med: 1.05 Max: 2.15
Current: 0.23
0.15
2.15
Price/Graham Number 0.56
FLDM's Price/Graham Number is ranked higher than
91% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. FLDM: 0.56 )
Ranked among companies with meaningful Price/Graham Number only.
FLDM' s Price/Graham Number Range Over the Past 10 Years
Min: 0.8  Med: 3.67 Max: 6.88
Current: 0.56
0.8
6.88
Earnings Yield (Greenblatt) (%) -17.59
FLDM's Earnings Yield (Greenblatt) (%) is ranked lower than
77% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. FLDM: -17.59 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
FLDM' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -18.73  Med: 0.00 Max: 0
Current: -17.59
-18.73
0

More Statistics

Revenue(Mil) $115
EPS $ -1.86
Beta2.82
Short Percentage of Float24.25%
52-Week Range $4.84 - 46.38
Shares Outstanding(Mil)28.79

Analyst Estimate

Dec16 Dec17
Revenue(Mil) 125 148
EPS($) -2.22 -1.76
EPS without NRI($) -2.22 -1.76

Latest Earnings Webcast

Call starts at Feb 04, 2016 05:00 PM EST

» More Conference Calls

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:FLB.Germany,
Fluidigm Corp is a Delaware Corporation formed in May, 1999. The Company develops, manufacture, and market microfluidic systems to academic institutions, clinical laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology (Ag-Bio) companies in growth markets, such as single-cell genomics, applied genotyping, and sample preparation for targeted resequencing. These systems are designed to simplify experimental workflow, increase throughput, and reduce costs, while providing the excellent data quality demanded by customers. The current markets for its products include life science research, clinical research, and Ag-Bio. The proprietary microfluidic systems consist of instruments and consumables, including integrated fluidic circuits (IFCs), assays, and reagents. The Company's primary area of development within life science research is genetic analysis, the study of genes and their functions. Genetic analysis techniques, such as SNP genotyping, genotyping by sequencing, and genotyping by real-time PCR analysis, have become increasingly useful in Ag-Bio applications, including wildlife population studies, agricultural quality control, and commercial genetic engineering and identification. It actively market four microfluidic systems, including 18 different commercial IFCs for nucleic acid analysis, as well as three families of assay chemistries. Its systems are based on one or more IFCs designed for particular applications and include specialized reagents, instrumentation, and software. The Company distributes its microfluidic systems through its direct sales force and support organizations located in North America, Europe, and Asia-Pacific, and through distributors or sales agents in several European, Latin American, Middle Eastern, and Asia-Pacific countries. It has sold its C1 Single-Cell Auto Prep, BioMark, BioMark HD, EP1, and Access Array systems to the academic institutions, clinical laboratories, and pharmaceutical, biotechnology and Ag-Bio companies. The Company has sold approximately 920 systems to customers in over 35 countries. Its microfluidic systems and instrumentation for commercial sale, as well as for internal research and development purposes, are manufactured at its facilities in Singapore. The Company also manufactures IFCs for research and development and its assay chemistries at its headquarters in South San Francisco, California. It competes with companies such as Affymetrix, Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Life Technologies Corporation (now part of Thermo Fisher Scientific), LGC Limited, Luminex Corporation, NanoString Technologies, Inc., PerkinElmer, Inc. (through its acquisition of Caliper Life Sciences, Inc.), RainDance Technologies, Inc., Roche Applied Science (a division of Roche Diagnostics Corporation), Sequenom, Inc., Thermo Fisher Scientific Inc., and WaferGen Bio-Systems, Inc.
» More Articles for FLDM

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Fluidigm Q4 Loss Narrower than Expected, Revenues Fall Y/Y Feb 10 2016
Fluidigm Corp. Earnings Analysis: 2015 By the Numbers Feb 08 2016
Edited Transcript of FLDM earnings conference call or presentation 4-Feb-16 10:00pm GMT Feb 05 2016
Fluidigm reports 4Q loss Feb 04 2016
Fluidigm reports 4Q loss Feb 04 2016
FLUIDIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 04 2016
Fluidigm Announces Fourth Quarter and Full Year 2015 Financial Results Feb 04 2016
Q4 2015 Fluidigm Corp Earnings Release - After Market Close Feb 04 2016
FLUIDIGM TO ANNOUNCE Q4-FULL YEAR 2015 FINANCIAL RESULTS Jan 28 2016
Fluidigm to Announce Q4-Full Year 2015 Financial Results and Host Conference Call for Investors Jan 28 2016
Fluidigm's Q4 Preliminary Results Fail to Woo Investors Jan 19 2016
FLUIDIGM ANNOUNCES PRELIMINARY FULL YEAR AND FOURTH QUARTER Jan 12 2016
FLUIDIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jan 12 2016
Fluidigm Announces Preliminary Full Year and Fourth Quarter 2015 Revenue Jan 12 2016
Coverage initiated on Fluidigm by Deutsche Bank Jan 07 2016
Fluidigm Mutes the Performance of IHI’s Small Caps Dec 24 2015
Pre-market Insights on Healthcare Sector -- Fluidigm, AngioDynamics, Tandem Diabetes Care, and... Dec 23 2015
The iShares US Medical Devices ETF (IHI) Has Put Nothing under the Tree in December—Yet Dec 16 2015
FLUIDIGM CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Dec 14 2015
Today's Market Driven by Key Factors - Free Research on Koppers Holdings, Dimension Therapeutics,... Dec 14 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK